신경 스테로이드의 항우울 효과

키워드

참고문헌 (50)

1. Hasin DS, "Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States", JAMA Psychiatry, 75, pp.336~346 (2018)
2. Pigott HE, "What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol", BMJ Open, 13, pp.e063095~ (2023)
3. Zhdanava M, "The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States", J Clin Psychiatry, 82, pp.20m13699~ (2021)
4. Sanchez C, "Vortioxetine, a novel antidepressant with multimodal activity : review of preclinical and clinical data", Pharmacol Ther, 145, pp.43~57 (2015)
5. Vecera CM, "Pharmacotherapies targeting GABA-glutamate neurotransmission for treatment-resistant depression", Pharmaceuticals(Basel), 16, pp.1572~ (2023)
6. McIntyre RS, "Glutamatergic modulators for major depression from theory to clinical use", CNS Drugs (2024)
7. Wang SM, "Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation : a meta-analysis", Clin Psychopharmacol Neurosci, 19, pp.341~354 (2021)
8. Tabuteau H, "Effect of AXS-05(dextromethorphan-bupropion)in major depressive disorder : a randomized double-blind controlled trial", Am J Psychiatry, 179, pp.490~499 (2022)
9. Iosifescu DV, "Efficacy and safety of AXS-05(dextromethorphan-bupropion)in patients with major depressive disorder : a phase 3 randomized clinical trial(GEMINI)", J Clin Psychiatry, 83, pp.21m14345~ (2022)
10. Hitt EM, "Zuranolone : a narrative review of a new oral treatment for postpartum depression", Clin Ther, 46, pp.433~438 (2024)
11. Ahmad A, "Zuranolone for treatment of major depressive disorder : a systematic review and meta-analysis", Front Neurosci, 18, pp.1361692~ (2024)
12. Reddy DS, "Neurosteroids : endogenous role in the human brain and therapeutic potentials", Prog Brain Res, 186, pp.113~137 (2010)
13. Mendell AL, "Neurosteroid metabolites of gonadal steroid hormones in neuroprotection : implications for sex differences in neurodegenerative disease", Front Mol Neurosci, 11, pp.359~ (2018)
14. Tuem KB, "Neuroactive steroids : receptor interactions and responses", Front Neurol, 8, pp.442~ (2017)
15. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR)" (2022), American Psychiatric Association
16. Bixo M, "Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder", J Neuroendocrinol, 30, pp.e12553~ (2018)
17. Gao Q, "Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder : toward precise targets for translational medicine and drug development", Front Psychiatry, 14, pp.1140796~ (2023)
18. Armeni E, "Hormone therapy regimens for managing the menopause and premature ovarian insufficiency", Best Pract Res Clin Endocrinol Metab, 35, pp.101561~ (2021)
19. Harlow SD, "Executive summary of the stages of reproductive aging workshop+10 : addressing the unfinished agenda of staging reproductive aging", J Clin Endocrinol Metab, 97, pp.1159~1168 (2012)
20. Maki PM, "Guidelines for the evaluation and treatment of perimenopausal depression : summary and recommendations", J Womens Health(Larchmt), 28, pp.117~134 (2019)
21. Freeman EW, "Associations of hormones and menopausal status with depressed mood in women with no history of depression", Arch Gen Psychiatry, 63, pp.375~382 (2006)
22. Fidecicchi T, "Neuroendocrine mechanisms of mood disorders during menopause transition : a narrative review and future perspectives", Maturitas, 188, pp.108087~ (2024)
23. Slopien R, "Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause", Gynecol Endocrinol, 34, pp.144~147 (2018)
24. Hendrick V, "Hormonal changes in the postpartum and implications for postpartum depression", Psychosomatics, 39, pp.93~101 (1998)
25. Grötsch MK, "Allopregnanolone in the peripartum : correlates, concentrations, and challenges–a systematic review", Psychoneuroendocrinology, 166, pp.107081~ (2024)
26. Suryawanshi O 4th, "A comprehensive review on postpartum depression", Cureus, 14, pp.e32745~ (2022)
27. Osborne LM, "Lower allopregnanolone during pregnancy predicts postpartum depression : an exploratory study", Psychoneuroendocrinology, 79, pp.116~121 (2017)
28. Standeven LR, "Allopregnanolone and depression and anxiety symptoms across the peripartum : an exploratory study", Arch Womens Ment Health, 25, pp.521~526 (2022)
29. Schweizer-Schubert S, "Steroid hormone sensitivity in reproductive mood disorders : on the role of the GABAA receptor complex and stress during hormonal transitions", Front Med(Lausanne), 7, pp.479646~ (2021)
30. De Berardis D, "Treatment of premenstrual dysphoric disorder(PMDD)with a novel formulation of drospirenone and ethinyl estradiol", Ther Clin Risk Manag, 3, pp.585~590 (2007)
31. Ma S, "Oral contraceptives containing drospirenone for premenstrual syndrome", Cochrane Database Syst Rev, 6, pp.CD006586~ (2023)
32. Barone JC, "A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders : studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy", Front Neuroendocrinol, 71, pp.101098~ (2023)
33. Zhang J, "The effect of exogenous estrogen on depressive mood in women : a systematic review and meta-analysis of randomized controlled trials", J Psychiatr Res, 162, pp.21~29 (2023)
34. Riebel M, "Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression", Eur Arch Psychiatry Clin Neurosci (2024)
35. Garcia-Argibay M, "Association of 5α-reductase inhibitors with dementia, depression, and suicide", JAMA Netw Open, 5, pp.e2248135~ (2022)
36. Pompili M, "Risk of depression associated with finasteride treatment", J Clin Psychopharmacol, 41, pp.304~309 (2021)
37. Walther A, "Association of testosterone treatment with alleviation of depressive symptoms in men : a systematic review and meta-analysis", JAMA Psychiatry, 76, pp.31~40 (2019)
38. Maharjan DT, "Testosterone in female depression : a meta-analysis and mendelian randomization study", Biomolecules, 11, pp.409~ (2021)
39. Maguire J, "Neuroactive steroids and GABAergic involvement in the neuroendocrine dysfunction associated with major depressive disorder and postpartum depression", Front Cell Neurosci, 13, pp.83~ (2019)
40. Powell JG, "Brexanolone(Zulresso) : finally, an FDA-approved treatment for postpartum depression", Ann Pharmacother, 54, pp.157~163 (2020)
41. Barnes KN, "Zuranolone : the first FDA-approved oral treatment option for postpartum depression", Ann Pharmacother, 58, pp.728~734 (2024)
42. Althaus AL, "Preclinical characterization of zuranolone(SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator", Neuropharmacology, 181, pp.108333~ (2020)
43. Takasu K, "Distinct mechanisms of allopregnanolone and diazepam underlie neuronal oscillations and differential antidepressant effect", Front Cell Neurosci, 17, pp.1274459~ (2024)
44. Clayton AH, "Zuranolone for the treatment of adults with major depressive disorder : a randomized, placebo-controlled phase 3 trial", Am J Psychiatry, 180, pp.676~684 (2023)
45. Epperson CN, "Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression : pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program", J Affect Disord, 320, pp.353~359 (2023)
46. Garafola S, "Safety of brexanolone in adults with postpartum depression : postmarketing surveillance data", Drugs Real World Outcomes, 10, pp.351~356 (2023)
47. Deligiannidis KM, "Effect of zuranolone vs placebo in postpartum depression : a randomized clinical trial", JAMA Psychiatry, 78, pp.951~959 (2021)
48. Mullard A, "FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder", Nat Rev Drug Discov, 22, pp.774~ (2023)
49. Cutler AJ, "Long-term safety and efficacy of initial and repeat treatment courses with zuranolone in adult patients with major depressive disorder : interim results from the open-label, phase 3 SHORELINE study", J Clin Psychiatry, 85, pp.23m14845~ (2023)
50. Prasad V, "Concerns that may limit the utility of zuranolone", JAMA, 331, pp.105~106 (2024)

관련 논문AI추천